Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2011 2
2012 1
2014 1
2015 1
2016 3
2017 2
2019 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.
Pimentel M, Morales W, Chua K, Barlow G, Weitsman S, Kim G, Amichai MM, Pokkunuri V, Rook E, Mathur R, Marsh Z. Pimentel M, et al. Dig Dis Sci. 2011 Jul;56(7):2067-72. doi: 10.1007/s10620-011-1728-5. Epub 2011 May 11. Dig Dis Sci. 2011. PMID: 21559740
After exclusion criteria were applied, subjects who had received rifaximin and were seen for retreatment were fully reviewed. During review, demographic information, duration of response, and success of treatment and retreatment were evaluated. ...More than 7 …
After exclusion criteria were applied, subjects who had received rifaximin and were seen for retreatment were fully reviewed. …
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.
Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Yang J, et al. Dig Dis Sci. 2008 Jan;53(1):169-74. doi: 10.1007/s10620-007-9839-8. Epub 2007 May 23. Dig Dis Sci. 2008. PMID: 17520365
PURPOSE: Previous studies demonstrate improvement in IBS after antibiotic therapy, with the greatest efficacy seen with the antibiotic, rifaximin. The purpose of this study was to compare the efficacy of rifaximin in both the treatment and retreatment of IBS. …
PURPOSE: Previous studies demonstrate improvement in IBS after antibiotic therapy, with the greatest efficacy seen with the antibiotic, r …
Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F, Lembo A. Cremonini F, et al. Expert Opin Pharmacother. 2012 Feb;13(3):433-40. doi: 10.1517/14656566.2012.651458. Epub 2012 Jan 18. Expert Opin Pharmacother. 2012. PMID: 22251066 Review.
Rifaximin pharmacodynamics, clinical pharmacology and results of clinical studies from proof of concept to the latest Phase III and retreatment studies in IBS are summarized. Challenges to rifaximin use, safety issues and regulatory data are also discussed. E …
Rifaximin pharmacodynamics, clinical pharmacology and results of clinical studies from proof of concept to the latest Phase III and …
Is irritable bowel syndrome an infectious disease?
Thompson JR. Thompson JR. World J Gastroenterol. 2016 Jan 28;22(4):1331-4. doi: 10.3748/wjg.v22.i4.1331. World J Gastroenterol. 2016. PMID: 26819502 Free PMC article. Review.
Antibiotic trials with both neomycin and rifaximin show improvement in global IBS symptoms that correlates with breath test normalization in diarrhea-predominant patients. The treatment response to two weeks of rifaximin is sustained for up to ten weeks and comparab …
Antibiotic trials with both neomycin and rifaximin show improvement in global IBS symptoms that correlates with breath test normaliza …
Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
Shah ED, Saini SD, Chey WD. Shah ED, et al. Clin Gastroenterol Hepatol. 2019 Dec;17(13):2687-2695.e11. doi: 10.1016/j.cgh.2019.02.039. Epub 2019 Mar 1. Clin Gastroenterol Hepatol. 2019. PMID: 30831219 Free PMC article.
We assessed the cost effectiveness of rifaximin in management of patients with irritable bowel syndrome with diarrhea (IBS-D) under common payer coverage restrictions and determined the maximum price at which rifaximin would be cost effective using contemporary cost …
We assessed the cost effectiveness of rifaximin in management of patients with irritable bowel syndrome with diarrhea (IBS-D) under c …
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP. Lembo A, et al. Gastroenterology. 2016 Dec;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. Epub 2016 Aug 13. Gastroenterology. 2016. PMID: 27528177 Free article. Clinical Trial.
Those responding to a 2-week course of open-label rifaximin 550 mg 3 times daily, who then relapsed during an observation phase (up to 18 weeks), were randomly assigned to groups given repeat treatments of rifaximin 550 mg or placebo 3 times daily for 2 weeks. ...RE …
Those responding to a 2-week course of open-label rifaximin 550 mg 3 times daily, who then relapsed during an observation phase (up t …
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Cash BD, Pimentel M, Rao SSC, Weinstock L, Chang L, Heimanson Z, Lembo A. Cash BD, et al. Ther Adv Gastroenterol. 2017 Sep;10(9):689-699. doi: 10.1177/1756283X17726087. Epub 2017 Sep 11. Ther Adv Gastroenterol. 2017. PMID: 28932270 Free PMC article.
BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-re …
BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsys …
Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review.
Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Schmulson M, et al. Rev Gastroenterol Mex. 2014 Apr-Jun;79(2):96-134. doi: 10.1016/j.rgmx.2014.01.004. Epub 2014 May 23. Rev Gastroenterol Mex. 2014. PMID: 24857420 Free article. Review. English, Spanish.
Retreatment effectiveness appears to be similar to that of the first cycle. CONCLUSIONS: Further studies are required to determine the nature of the gut microbiota in IBS and the differences in low-grade inflammation between PI-IBS and non-PI-IBS. Rifaximin has show …
Retreatment effectiveness appears to be similar to that of the first cycle. CONCLUSIONS: Further studies are required to determine th …
Novel Therapies in IBS-D Treatment.
Nee J, Zakari M, Lembo AJ. Nee J, et al. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5. Curr Treat Options Gastroenterol. 2015. PMID: 26432092
Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad spectrum gut specific antibiotic, were both FDA approved in 2015. Eluxadoline has been shown to relieve abdominal pain and stool consistency in appropriate candidates. While large trials already showed the effi …
Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad spectrum gut specific antibiotic, were both FDA approved in 2015. Elux …
12 results